论文部分内容阅读
江苏迈迪基因生物科技有限公司是“530”企业,其董事长、无锡市生物医药协会副会长邵棠博士,邵棠出生于湖北仙桃,1986年毕业于同济医科大学(现为华中科技大学同济医学院),随后在北京医科大学(现为北京大学医学部)任内科医师。1989年赴美国留学,并成为美国南加州大学分子微生物学和免疫学的博士后,从事生物医学的基础研究。于2003年开始创办了美国加州Genetech USA技术公司,并先后担任首席科学家及总裁。他和团队利用最先进的基因重组和分子克隆技术,在美国研发出了最新一代的基因工程非处方药品,并通过严格的人体临床试验后获得了美国FDA的批准。同时,美国公司重点研发心血管疾病生物标记物和血液系统肿瘤基因的液相芯片检测产品,并且完成了诊断试剂盒的研发和批量生产。
Jiangsu Meidi Biotechnology Co., Ltd. is a “530” enterprise. Its chairman and Dr. Shao Tang, vice chairman of Wuxi Biomedicine Association, was born in Hubei Xiantao. He graduated from Tongji Medical University in 1986 Tongji Medical College), then physician at Beijing Medical University (now Peking University Health Science Department). In 1989 to study in the United States, and became the University of Southern California molecular microbiology and immunology postdoctoral, engaged in basic research in biomedicine. In 2003, he founded the Genetech USA technology company in California, USA, and successively served as Chief Scientist and President. He and his team used state-of-the-art gene recombination and molecular cloning techniques to develop the latest generation of genetically engineered over-the-counter drugs in the United States and obtained FDA approval for their use in rigorous human clinical trials. At the same time, the American company focused on the development of liquid-chip detection products of cardiovascular disease biomarkers and hematological oncogenes, and completed the development and mass production of diagnostic kits.